Genvoya is a fixed-dose tablet combining 150mg of elvitegravir, 150mg of cobicistat, 200mg of emtricitabine and 10mg of tenofovir alafenamide (TAF). It is manufactured by Gilead Sciences.

Elvitegravir is an integrase inhibitor. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI). These drugs reduce the amount of HIV in the body. Cobicistat is an agent used to boost levels of elvitegravir. It has no anti-HIV activity of its own. Genvoya provides a full anti-HIV drug combination in one pill.

Genvoya received marketing approval in the United States and European Union in November 2016.

The standard dose of Genvoya is one pale green tablet once day, taken with food. It is licensed for use in adults over 18 years of age.

For more information on Genvoya’s component drugs, including drug interactions, side-effects and resistance, see elvitegravir, emtricitabine and tenofovir (Viread).

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.